The Quantellect read.As of Nov 19, 2026, 6 active firms cover Pelthos Therapeutics Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.45 next quarter toward $-9.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 19, 2026 vs $6.96 current
Highest Target—
Average Target—
Lowest Target—
PTHS analyst recommendation trends
86420
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
6
6
6
6
6
6
Neutral
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
6
6
6
6
6
6
As of Nov 19, 2026, 6 of 6 active firms rate PTHS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PTHS EPS & revenue forecast
EPS · NEXT QUARTER
$-2.45
Range $-2.45 – $-2.45 · 1 analysts · -47% YoY
Next period, 1 analysts expect Pelthos Therapeutics Inc. to earn $-2.45 a share (range $-2.45 – $-2.45), versus $-4.66 a year earlier. Full-year consensus is $-17.60, growing to $-9.12 the year after.
REVENUE · NEXT QUARTER
$17.3M
Range $14.0M – $19.0M · 1 analysts · +59% YoY
Revenue is expected to reach $17.3M (range $14.0M – $19.0M), +58.6% year-over-year. Full-year consensus is $57.9M, rising to $92.0M next year.
Top analysts covering Pelthos Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PTHS.
#1
David Amsellem
Piper Sandler · Rank #124
Buy
$48.00+589.7% to target
Overall win rate
50%
+ Follow
#2
TF
Thomas Flaten
Lake Street · Rank #306
Buy
$40.00+474.7% to target
Overall win rate
40%
+ Follow
#3
Jeff Jones
Oppenheimer · Rank #320
Buy
$64.00+819.5% to target
Overall win rate
32%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$60.00+762.1% to target
Overall win rate
38%
+ Follow
#5
Jonathan Aschoff
Roth MKM · Rank #588
Buy
$55.00+690.2% to target
Overall win rate
28%
+ Follow
PTHS stock forecast FAQ
Is PTHS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover PTHS?+
6 active firms have a recognized rating on Pelthos Therapeutics Inc. as of Nov 19, 2026.
Who is the most accurate analyst covering PTHS?+
Among analysts who currently cover PTHS, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #124). Their current call is Buy with a $48.00 target.
What is Pelthos Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-2.45 per share (range $-2.45 – $-2.45) across 1 analysts. Full-year EPS is projected at $-17.60, rising to $-9.12 the following year.
How much revenue is Pelthos Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $17.3M (range $14.0M – $19.0M). Full-year revenue is projected at $57.9M, growing to $92.0M next year.
Have analysts been upgrading or downgrading PTHS lately?+
As of Nov 19, 2026, 6 of 6 active firms rate PTHS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PTHS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.